TREATMENT OF RENAL CARCINOMA IN A BINTURONG (ARCTICTIS BINTURONG) WITH NEPHRECTOMY AND A TYROSINE KINASE INHIBITOR

被引:1
|
作者
Thompson, Kimberly A. [1 ]
Patterson, Jon [2 ]
Fitzgerald, Scott D. [2 ]
Needle, David [2 ,3 ]
Harrison, Tara [1 ,4 ]
机构
[1] Michigan State Univ, Coll Vet Med, 784 Wilson Rd, E Lansing, MI 48824 USA
[2] Michigan State Univ, Diagnost Ctr Populat & Anim Hlth, Coll Vet Med, 4125 Beaumont Rd, Lansing, MI 48824 USA
[3] Univ New Hampshire, New Hampshire Vet Diagnost Lab, 21 Bot Lane, Durham, NH 03824 USA
[4] North Carolina State Univ, Dept Clin Sci, 1060 William Moore Dr, Raleigh, NC 27607 USA
关键词
Arctictis binturong; binturong; nephrectomy; renal adenocarcinoma; toceranib phosphate; tyrosinekinase inhibitor; CELL CARCINOMA; HYPERCALCEMIA; CANINE;
D O I
10.1638/2015-0285.1
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
A 13-yr-old female binturong (Arctictis binturong) presented with a 1 wk history of decreased appetite. The animal was thin, with hypercalcemia (calcium 12.2 mg/dl). A right renal mass was identified on ultrasound and removed via nephrectomy. Histopathology indicated a renal adenocarcinoma. Treatment with toceranib phosphate, a tyrosine-kinase inhibitor, was initiated and well tolerated by the animal. Four months after initial diagnosis radiographs indicated metastases to the lungs and the animal was euthanized. Necropsy revealed disseminated adenocarcinoma. Although treatment did not prevent metastasis, it was minimally invasive and well tolerated by the animal with minimal side effects. Review of records at the institution revealed that the cause of death for the primary case's dam and sire was disseminated renal carcinoma. These cases suggest that there may be a hereditary component to development of renal neoplasia in binturongs. Renal carcinoma should be considered an aggressive neoplasia in binturongs with a poor prognosis.
引用
收藏
页码:1109 / 1113
页数:5
相关论文
共 50 条
  • [1] Sarcomatoid renal cell carcinoma in a binturong (Arctictis binturong)
    Childs-Sanford, SE
    Peters, RM
    Morrisey, JK
    Alcaraz, A
    JOURNAL OF ZOO AND WILDLIFE MEDICINE, 2005, 36 (02) : 308 - 312
  • [2] Renal adenocarcinoma, hepatocellular carcinoma, and pancreatic islet cell carcinoma in a binturong (Arctictis binturong)
    Klaphake, E
    Shoieb, A
    Ramsay, E
    Schumacher, J
    Craig, L
    JOURNAL OF ZOO AND WILDLIFE MEDICINE, 2005, 36 (01) : 127 - 130
  • [4] Trends in the use of cytoreductive nephrectomy for metastatic renal cell carcinoma in the VEGFR tyrosine kinase inhibitor era
    Tsao, Che-Kai
    Small, Alexander C.
    Kates, Max
    Gartrell, Benjamin Adam
    Wisnivesky, Juan P.
    Sonpavde, Guru
    Palese, Michael
    Hall, Simon
    Oh, William K.
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Cytoreductive Nephrectomy in Metastatic Clear-Cell Renal Cell Carcinoma: Perspectives in the Tyrosine Kinase Inhibitor Era
    Biswas, Swethajit
    Kelly, John
    Eisen, Tim
    ONCOLOGIST, 2009, 14 (01): : 52 - 59
  • [6] BILATERAL RENAL CELL CARCINOMA: NEOADJUVANT TYROSINE KINASE INHIBITOR HELPS PRESERVE RENAL FUNCTION PRIOR TO ROBOTIC PARTIAL NEPHRECTOMY
    Zeng, Jiping
    Lwin, Aye
    Wong, Ava
    Batai, Ken
    Lee, Benjamin
    JOURNAL OF UROLOGY, 2021, 206 : E208 - E208
  • [7] ROBOTIC PARTIAL NEPHRECTOMY FOLLOWING NEOADJUVANT TYROSINE KINASE INHIBITOR TREATMENT
    White, Michael A.
    Spana, Gregory
    Hillyer, Shahab
    Rini, Brian I.
    Campbell, Steven C.
    Kaouk, Jihad H.
    JOURNAL OF UROLOGY, 2011, 185 (04): : E412 - E412
  • [8] MCT INHIBITION SYNERGIZES WITH TYROSINE KINASE AND MTOR INHIBITOR TREATMENT IN RENAL CELL CARCINOMA
    Jambunathan, Bhaghyasree
    Dergham, Abdo
    Bhattacharjee, Sayani
    Wynn, Rebecca
    Sindhwani, Puneet
    Petros, Firas
    Nadiminty, Nagalakshmi
    JOURNAL OF UROLOGY, 2022, 207 (05): : E702 - E702
  • [9] Pazopanib The Newest Tyrosine Kinase Inhibitor for the Treatment of Advanced or Metastatic Renal Cell Carcinoma
    Keisner, Sidney V.
    Shah, Sachin R.
    DRUGS, 2011, 71 (04) : 443 - 454
  • [10] Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3
    Penel, Nicolas
    BULLETIN DU CANCER, 2017, 104 (09) : 705 - 706